Alnylam's Amvuttra Tests Faster HTA In England, Wins Praise in Germany For Full Assessment
Alnylam has opted to submit its orphan drug Amvuttra for a full benefit assessment in Germany, rather than an abbreviated process that requires no comparative data. In England, the drug was recommended following a pilot for designing a new and faster approach to health technology appraisals.
You may also be interested in...
Ngenla and Ofev are the first two drugs to be evaluated using the health technology appraisal institute’s new proportionate approach – they were both appraised much faster than usual.
A new law aimed at limiting drug spending in Germany will mean that only companies with new products that offer high levels of added benefit will have full flexibility to negotiate prices.
Industry has warned that reforming the system for evaluating orphan drugs could have serious consequences for patient access.